Mirum Pharmaceuticals, Inc. SEC Filing
Earlier reported sales included 30,000 shares on September 1 and 20,000 shares on August 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Mirum Pharmaceuticals, Inc. (MIRM) officer and director Christopher James Peetz reported a proposed sale of 20,000 common shares, with an aggregate market value of $1,800,000.00 and an approximate sale date of November 4, 2026. Morgan Stanley Smith Barney LLC is listed as the broker; the shares are described as acquired from the issuer through a stock option exercise for cash on November 4, 2026. The notice also lists sales of 30,000 shares on September 1, 2026, and 20,000 shares on August 10, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.